-
摘要: [目的]探讨康复新液联合埃索美拉唑治疗慢性糜烂性胃炎(CEG)的效果及对患者血清炎症因子水平的影响。[方法]选取我院消化内科收治的CEG患者60例(2013年1月~2016年1月)进行回顾性分析,其中观察组30例(康复新液联合埃索美拉唑结合基础治疗)、对照组(果胶铋联合埃索美拉唑结合基础治疗)30例,疗程4周。[结果]观察组痊愈76.67%、显效20.00%、有效3.33%,对照组50.00%、显效36.67%、有效10.00%、无效3.33%,2组比较差异有统计学意义(P<0.05);治疗前,观察组和对照组的血清表皮生长因子、IL-6、TNF-α、GAS、MTL检测水平差异均无统计学意义(P>0.05);治疗后,观察组血清表皮生长因子、IL-6、TNF-α、检测水平低于对照组(P<0.05),观察组的血清GAS、MTL水平高于对照组(P<0.05);治疗后,观察组Hp转阴率68.75%与对照组的57.14%比较,差异无统计学意义(P>0.05)。[结论]康复新液联合埃索美拉唑治疗CEG效果较好,能显著的减轻患者的炎症反应。Abstract: [Objective]Study of Kangfuxin Liquid combined with esomeprazole in the treatment of chronic erosive gastritis(CEG)and its effect on the level of serum inflammatory factors in patients.[Methods]60 CEG patients in our hospital(January 2013 to January 2016)were analyzed retrospectively,including 30 cases of observation group(basic treatment combined with Kangfuxin Liquid Combined with esomeprazole)and 30 cases of control group(treated with bismuth pectin combined with esomeprazole).[Results]The 76.67% cases were cured,20% cases had marked effect,3.33% cases had effect in observation group.The 50.00% cases were cured,36.67% cases had marked effect,10.00% cases had effect and 3.33% without effect in control group.There were statistically significant differences between the two groups(P＜0.05);before treatment,observation group and control group of serum epidermal growth factor,IL-6,TNF-,GAS,MTL.The detection level had no statistically significant difference(P＞0.05);after treatment,the observation group of serum epidermal growth factor,IL-6,TNF-,alpha detection level is lower than the control group(P＜0.05),to observe the serum GAS,MTL levels were higher than that of the control group(P＜0.05);after treatment,the observation group compared with the control group of 68.75% Hp negative rate 57.14%(P＞0.05).[Conclusion]Kangfuxin Liquid combined with esomeprazole is effective in treatment with CEG,it can significantly reduce the inflammatory reaction.
-
Key words:
- Kangfuxin Liquid /
- esomeprazole /
- chronic erosive gastritis /
- inflammatory factors
-
-
[1] 唐莉.单兆伟益气清热护膜法治疗慢性糜烂性胃炎的思路[J].江苏中医药, 2015, 2 (2):19-20.
[2] Kilincalp S, Bager P, Karaahmet F, et al.Letter:Effects of gastric microenvironment on the management of iron deficiency anaemia[J].Alimentary Pharmacology and Therapeutics, 2014, 39 (5):551-552.
[3] 中华医学会消化病学分会幽门螺杆菌学组.幽门螺杆菌胃炎京都全球共识研讨会纪要[J].中华消化杂志, 2016, 1 (1):53-57.
[4] 孙晓红.中国功能性消化不良专家共识意见 (2015年, 上海) 解读:非常规药物治疗[J].中华消化杂志, 2016, 36 (4):239-240.
[5] 陈烨.幽门螺杆菌胃炎是一种感染性疾病[J].中华消化杂志, 2016, 1 (1):8-10.
[6] 高文, 胡伏莲, 成虹, 等.国产药物组成的四联疗法对胃炎及十二指肠溃疡患者幽门螺杆菌感染根除效果的前瞻性多中心随机对照研究[J].中华医学杂志, 2016, 96 (4):260-264.
[7] 薛翔, 聂时南.抑酸治疗在应激溃疡中预防性治疗的作用及不良反应[C].//中华医学会急诊医学分会第17次全国急诊医学学术年会论文集.2014:683-683.
[8] 刘改芳, 朱新影, 吴婧, 等.以兰索拉唑口崩片和埃索美拉唑镁肠溶片为基础的四联方案根除幽门螺杆菌疗效分析[J].中华临床感染病杂志, 2016, 9 (6):522-524.
[9] 刘世雄, 赵丽, 周芸, 等.二甲双胍联合埃索美拉唑对老年2型糖尿病患者血清胃泌素和血糖的影响[J].中华老年医学杂志, 2016, 35 (4):405-408.
[10] 綦素霞, 亓玉琴, 咸会波, 等.改良四联疗法治疗幽门螺杆菌根除失败病例的疗效[J].中华临床感染病杂志, 2015, (4):337-339.
[11] 陈继兰, 刘童婷, 黄秀深, 等.康复新液对促进实验性胃溃疡愈合过程中病理变化的影响[C].//中华中医药学会第十五次中医方剂学学术年会论文集.2015:198-202.
[12] 刘希, 成虹, 高文, 等.含阿莫西林和呋喃唑酮四联疗法补救治疗幽门螺杆菌感染的效果及安全性[J].中华医学杂志, 2014, 94 (8):567-571.
[13] 王雪华, 曹燕, 张剑宏, 等.血清胃蛋白酶原联合胃泌素测定在胃癌及萎缩性胃炎中的诊断价值[J].中华临床医师杂志 (电子版), 2015, 9 (10):62-65.
[14] 黄敏, 刘慧玲, 余贻汉, 等.2型糖尿病患者幽门螺杆菌感染炎症因子水平及调控因子活性的变化[J].中华医院感染学杂志, 2014, 7 (9):2211-2213.
[15] Vasiliou C, Xiromeritou V, Kafiri G, et al.Endoscopic and Histological Findings and Helicobacter pylori Status in Patients With Reflux and/or Dyspeptic Symptoms A Recent Greek Cohort Study[J].Gastroenterol nurs, 2014, 37 (6):431-438.
-
计量
- 文章访问数: 156
- PDF下载数: 280
- 施引文献: 0
下载: